Bronchodilator effects of aclidinium bromide, a novel long-acting anticholinergic, in COPD patients: a phase II study Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Once-daily administration of aclidinium bromide, a novel, long-acting anticholinergic: a phase II, dose-finding study Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Rapid plasma hydrolysis of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
The preclinical urinary and renal safety profile of aclidinium bromide, a novel long-acting anticholinergic drug Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
ACCLaim/COPD II: efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a phase III study Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
The efficacy of long-acting anticholinergic agent, tiotropium bromide on dynamic hyperinflation in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
The potential cost-effectiveness of glycopyrronium bromide, a novel LAMA Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012
Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012
Aclidinium bromide, a novel long-acting anticholinergic, does not affect QT interval in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Source: Eur Respir J 2012; 40: 1106-1114 Year: 2012
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 72s Year: 2001